乌司他丁治疗全身炎症反应综合征的临床研究

Clinical study of the therapeutic value of the Ulinastatin in systemic inflammatory response syndrome (SIRS)

目的研究乌司他丁(UTI)治疗全身炎症反应综合征(SIRS)的临床疗效以及对炎性介质的影响,了解UTI对SIRS的治疗价值。方法选择符合SIRS诊断标准的48例患者,随机分为UTI治疗组(A组)和常规治疗组(B组)。观察两组患者的临床效果并检测治疗前后血清IL-6、TNFα、C-反应蛋白(CRP)、IL-10水平变化。结果治疗后A组患者临床症状改善较B组明显,MODS发生率下降,炎性介质CRP、IL-6、TNFα、IL-10水平在A组改变较B组明显。结论乌司他丁能改善SIRS的临床症状,对炎性介质起免疫调理作用。

Objective To observe the therapeutic value of the Ulinastatin in critical illness cases with SIRS by comparison between Ulinastatin group and no Ulinastatin groups. Methods The 48 SIRS patients according to the diagnosis criteria of SIRS were randomly divided into regular treatment group (group B) and Ulinastatin treatment group (group A). The efficacy of the therapy in both the groups were assessed and serum CRP, TNF-α,IL-6 and IL-10 levels were measured on admission and on the fifth day in both the group. Results SIRS markers all reduced more significantly in group A than in group B(P<0.01). Serum CRP, TNF-α and IL-6 levels reduced more significantly in group A than in group B ( P <0.01). Serum CRP, TNF-α and IL-6 levels reduced more significantly after treatment in group A than in group B (P<0.01). IL-10 rose significantly after treatment in group A(P<0.05), but it didn't change significantly after treatment in group B ( P >0.05). Conclusion Ulinastatin improved significantly the clinical effects of SIRS, prevented the MODS incidence, prohibited the inflammatory cytokinases and raised the anti-inflammatory cytokinases in the treatment of SIRS. [